UniQure’s etranacogene dezaparvovec in haemophilia B has experts positive on Phase III prospects

UniQure claims that preclinical data shows AAV5-based gene therapies such as etranacogene dezaparvovec may be clinically effective in patients with pre-existing antibodies to AAV5. Credit: anyaivanova / Shutterstock.



  • etranacogene dezaparvovec